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 The impact of Alzheimer’s Disease (AD) on today’s society and healthcare is 
unprecedented. As a larger portion of today’s population enters an age for which AD becomes a 
health concern, there is growing support among health practitioners to prevent the disease’s 
progression and development. Early identification of the disease may serve as a critical step 
towards combating the disease, allowing earlier interventions in the disease process to foster 
healthy aging. The focus of such interventions includes alleviating risk factors of AD, two of 
which include cortisol and degeneration in the basal forebrain. Importantly, increased levels of 
cortisol and reduced volume in the basal forebrain are attributed to higher risks of AD. In the 
present study, we make use of machine learning and the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) database to characterize individuals with AD by using data from cortisol levels 
and basal forebrain degeneration. This allowed us to test whether cortisol and basal forebrain 
degeneration were predictively valuable for AD diagnosis. Our data partially supported our 
prediction—the machine learning classifier yielded significantly above chance classification 
accuracy for basal forebrain degeneration, but the classification accuracy for cortisol was not 
significantly above chance. Consequently, our results indicate that basal forebrain degeneration 
might serve as a diagnostically useful biomarker for AD, while cortisol’s role in AD 












 Alzheimer’s Disease (AD) is one of the most common forms of dementia facing patient 
populations today. Characterized by progressive and often irreversible cognitive decline, AD is a 
serious public health issue that preferentially affects elderly populations. AD pathology involves 
a progression of events as individuals age. This progression may involve an intermediate case of 
pathology, mild cognitive impairment (MCI), which is distinct from healthy individuals and 
those with moderate AD. MCI patients exhibit memory differences when compared to healthy 
patients, while differing from mild AD patients in cognitive faculties other than memory 
(Petersen et al., 1999). The need to address Alzheimer’s Disease has become particularly 
relevant in recent years, with 1996 United Nations projections indicating that from 2000 to 2050, 
a significant increase in the proportion of the population above 65 years of age is to be expected 
(Katzman & Fox, 1999). This increase emphasizes the need to work towards identifying 
therapeutic strategies against AD. Due to the progressive nature of this neurodegenerative 
disease, identifying AD at early stages may be critical for preventing its progression and 
combating the pathology. Often times, AD is only recognized after the disease has irreversibly 
progressed, making successful patient outcomes less likely. Early diagnosis may allow for 
interventions to be implemented in order to potentially maintain cognitive function at high levels 
in individuals with Alzheimer’s Disease (Mueller et al., 2005). Early diagnosis could afford the 
possibility of disease treatment before AD irreversibly progresses, improving patient outcomes 
significantly.  
 Early diagnosis depends on recognizing biomarkers of interest that may be targeted with 
preclinical interventions in order to improve future outcomes for AD patients. Recent research 
has revealed that cortisol, a hormone that induces physiological responses to stress, may play a 
role in AD pathogenesis on account of its interaction with traditionally relevant AD markers. For 
example, rodent studies have established links between cortisol, cognitive impairment, and 
physiological anomalies (e.g. amyloid beta plaque and tau tangle formation). Researchers found 
that exposing amyloid beta-infused rats to chronic stress resulted in a greater significance in 
cognitive defects for short term memory, suggesting that stress may exacerbate cognitive decline 
in AD-pathological models (Srivareerat, Tran, Alzoubi, & Alkadhi, 2009). An additional study 
has also shown that glucocorticoid presence elevated amyloid beta presence in older mice and 
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localized tau abnormally. Based on the study, glucocorticoids seem to increase levels of these 
two crucial physiological markers of AD pathogenesis (Green, Billings, Roozendaal, McGaugh, 
& LaFerla, 2006). Studies in human participants also point out a potential role cortisol may play 
in AD pathology by showing that cortisol levels can be significantly higher in AD vs. control or 
MCI individuals (Popp et al., 2009). Indeed, research utilizing urinary free cortisol levels 
suggests that “elevated cortisol may affect age-related cognitive and brain changes and possibly 
facilitate the development of AD” (Ennis et al., 2017).  
 AD pathogenesis is also believed to be related to basal forebrain degeneration—which 
may interact with cortisol to contribute to a downstream deficiency of the neurotransmitter 
acetylcholine in memory systems within the brain. Basal forebrain projections target brain areas 
populated by glucocorticoid receptors (e.g. the medial temporal lobe memory system), indicating 
that basal forebrain degeneration may interact with cortisol levels in AD pathology (Paul, Jeon, 
Bizon & Han, 2015; Helm, Han, & Gallagher, 2002). Importantly, it has also been demonstrated 
that basal forebrain degeneration predicts deterioration in the medial temporal brain areas such as 
the entorhinal cortex (Schmitz et al., 2016). Finally, one study has pointed to the idea that a loss 
of basal forebrain connectivity may lead to increased cortisol levels that damage the brain in an 
AD-associated manner. The study specifically related age-associated degeneration of the basal 
forebrain to hypothalamic–pituitary–adrenal axis dysfunction in such a way that can lead to the 
development of AD (Paul, Jeon, Bizon & Han, 2015). 
 Fully cognizant of how important early diagnosis is in successfully treating AD, the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) constitutes an extensive program for 
integrating data regarding AD biomarkers from a community of researchers. This unprecedented 
program is designed not only to help diagnose AD and MCI, but also to provide insight into AD 
pathology and progression (Mueller et al., 2005). ADNI serves as a useful tool for developing 
AD diagnoses because its wealth of biomarker data adds power to statistically relevant 
conclusions drawn from the database.  
 In this study, we use the machine learning technique known as multivariate pattern 
analysis (MVPA) in order to classify AD individuals from cognitive normal (CN) individuals 
based on cortisol and basal forebrain degeneration. These predictors were independently used to 
evaluate how well the machine learning algorithm was capable of distinguishing between AD 
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and CN patients. This approach will allow for powerful insight into the predictive value of 
cortisol and basal forebrain degeneration in AD pathology and can help validate the importance 























Recent demographic trends illustrate that the current global population is composed of a 
growing proportion of elderly individuals. In fact, the proportion of our population above the age 
of 65 is expected to increase significantly from the year 2000 to 2050, according to United 
Nations predictions (Katzman & Fox, 1999). This alarming increase in the cohort of aging 
individuals presents a corresponding increase in the number of potential age-associated 
neurological deficits. In particular, AD preferentially affects individuals as they age. With an 
anticipated increase in the aging demographic, the need to address this issue has become salient 
in recent years.  
 AD is a neurodegenerative disorder characterized by a progressive decline in the number 
of neurons in the aging brain. This neurological disorder is exacerbated with time, and late-stage 
AD patients experience substantial decline in cognitive faculties, including memory. The 
physical and emotional toll of AD on both patients and their loved ones underscores why 
interventions to treat this disorder are particularly necessary. Current problems with treating AD 
include diagnosing and identifying the disease too late, at a point at which the disease has 
irreversibly progressed. To treat AD, early diagnosis has been noted as an important avenue 
through which early interventions can be applied to preserve patient function for longer periods 
of time (Khachaturian, 1985). Consequently, present scientific literature aims to answer the 
question of what biomarkers, metrics of interest that are indicative of AD, are especially useful 
in identifying the disease at an early, asymptomatic stage. Importantly, identifying these 
biomarkers also helps clarify the disease process by which AD leads to progressive, irreversible 
neurodegeneration.  
AD has traditionally been characterized by two pathophysiological processes and one 
common symptom. The pathophysiological processes associated with AD include the presence 
of amyloid beta and tau tangles, while the common symptom of this disorder is cognitive deficits 
(including significant memory loss). These three metrics all serve as the traditional markers by 
which AD is identified and by which AD may progress. As a result, tracking predictors of these 
markers has been explored as a way to achieve earlier diagnoses of Alzheimer’s Disease. While 
these traditional markers characterize AD progression, the search for biomarkers that may be 
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detected preclinically has enormous implications for treating this debilitating disease and 
promoting healthy aging.  
In pursuit of biomarkers to help clarify AD progression and help diagnose AD at early 
stages, cortisol and basal forebrain degeneration represent promising new biomarkers at the 
forefront of study. Cortisol is a hormone released by the adrenal cortex in response to stressful 
situations. Cortisol is known to induce a variety of changes to put the body in a state of “fight-or-
flight,” in which humans are better equipped to handle stressors in the environment. Multiple 
regions of the body express receptors to cortisol, and the brain is no exception. One particular 
area of the brain that is implicated in memory function, the hippocampus, is known to express 
extensive receptors for cortisol (McEwen & Sapolsky, 1995). In particular, studies have shown 
that prolonged exposure to cortisol can reduce hippocampal volume, a characteristic associated 
with neurodegenerative diseases such as AD (Kim, Pellman, & Kim, 2015). In fact, one study 
specifically concluded that increased cortisol measures could lead to the development of AD by 
inducing age-associated cognitive and neurological changes (Ennis et al., 2017). Alternatively, 
literature also proposes the idea that insufficient glucocorticoid signaling may lead to AD 
pathology: reduced cortisol signaling could allow pro-inflammatory processes to exacerbate 
brain damage and lead to the development of AD (Raison & Miller, 2003). Regardless, these 
findings, coupled with other literature findings, has motivated further research into cortisol as a 
potential pathophysiological property of AD. 
 Researchers have found that exposure of chronic stress to amyloid beta-infused rats 
resulted in more cognitive defects in short term memory, indicating that stress may cause 
cognitive decline in AD models (Srivareerat, Tran, Alzoubi, & Alkadhi, 2009). Additionally, 
glucocorticoids such as cortisol increased amyloid beta load in older mice and abnormally 
localized tau proteins. This finding reveals a potential relationship between cortisol and AD 
pathogenesis in the context of physiological biomarkers of AD (Green, Billings, Roozendaal, 
McGaugh, & LaFerla, 2006). Finally, the loss of basal forebrain connectivity can increase 
cortisol levels due to dysfunction in the hypothalamic-pituitary-axis. In doing so, individuals 
may then be more predisposed to develop AD in the future due to cognitive impairment (Paul, 
Jeon, Bizon & Han, 2015).  
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 Studies have also linked degeneration in the basal forebrain to the development of AD. 
The nucleus basalis of Meynert, a specific density of neurons within the basal forebrain, has been 
shown to undergo degeneration within Alzheimer’s patients, helping explain cholinergic 
insufficiency in these patients (Whitehouse et al., 1982). Studies also demonstrate a link between 
the aggregation of neocortical amyloid beta, a pathological biomarker of AD, and basal forebrain 
degeneration (Kerbler et al., 2015).  
 As discussed, a number of studies have now explored the relationship of cortisol and 
basal forebrain degeneration in the characterization of Alzheimer’s Disease pathology. In the 
present study, we make unique use of robust machine learning techniques (multivariate pattern 
analysis) to analyze how cortisol as well as basal forebrain degeneration can distinguish 
individuals who are cognitively normal from individuals who exhibit AD pathology. By using 
our current research approach, we hope to validate both cortisol and basal forebrain degeneration 

















The data obtained for this study came from a database known as the Alzheimer’s Disease 
Neuroimaging Initiative, ADNI (http://adni.loni.usc.edu/). Dr. Michael W. Weiner, Principle 
Investigator of ADNI, started this program in 2004 with the desire to establish an integrative 
database that was focused on accumulating a diverse set of data to assist in the early 
identification of Alzheimer’s Disease. Since its inception in 2004, ADNI data have allowed for a 
multitude of studies to explore the relationship between unique biomarkers and the development 
of Alzheimer’s Disease. The patients within the ADNI database were obtained from various sites 
within the United States and Canada. Before obtaining biomarker data, each patient provided 
written informed consent. More information regarding the database can be found at the ADNI 
website (http://adni.loni.usc.edu/).  
ADNI Sample Data 
The majority of this study’s data came from one spreadsheet that contained important data tables 
consolidated into one central location (a spreadsheet referred to as ADNIMERGE). Examples of 
biomarkers in this dataset included whole brain volume, age, ApoE4 genotype, and various other 
biomarkers. Cortisol biomarkers came from a separate spreadsheet, “Biomarkers Consortium 
Plasma Proteomics Project RBM.” Basal forebrain volume measurements were obtained from 
study participants who had structural MRI images taken of their brains. Not all of the study 
participants on the ANDIMERGE spreadsheet had cortisol values or structural MRI images. 
Based on the relevant data (cortisol and basal forebrain volume) that were present within the 
ADNIMERGE spreadsheet, a cortisol sample (n = 163) and basal forebrain sample (n = 94) were 
obtained for data analysis. Of the cortisol sample, 122 individuals had Alzheimer’s Disease (AD) 
while 41 were cognitively normal (CN). Of the basal forebrain sample, 41 individuals had AD 
while 53 were CN. 
Cortisol Measurements  
To obtain the cortisol measures, participants fasted overnight and provided blood samples the 
following day. The blood samples were centrifuged at room temperature and at 1500 RCF. The 
plasma from the blood samples was obtained and sent to the UPenn Bio-marker Core laboratory. 
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There, the plasma samples were stored at −80°C. When ready for testing, cortisol measures, 
along with other measurements, were calculated using guidelines by Rules-Based Medicine, Inc. 
(see http://www.rulesbasedmedicine.com for more information) (Toledo et al., 2013). 
“Biomarkers Consortium Plasma Proteomics Project RBM multiplex data” provided a 
spreadsheet within the ADNI database in which these cortisol measures were recorded for use in 
our study. 
Basal Forebrain Volumes 
In order to obtain basal forebrain volume measurements, structural MRI images for the relevant 
participants were first collected. Inclusion criteria in order to obtain basal forebrain volumes 
referred to participants within the ADNIMERGE spreadsheet for whom there was a T1 MRI 
image with 1.2 mm slice thickness. After obtaining the images, we used a procedure similar to 
that of Schmitz et al. 2016 in order to create a mask for the basal forebrain and extract volume 
measurements. Similar to Schmitz et al. 2016, this study chose to focus on the nucleus basalis of 
Meynert on account of the fact that this structure has been linked to neuronal cell loss in 
Alzheimer’s Disease (Arendt, Bigil, Arendt, & Tennstedt, 1983). Ch4, a cholinergic cell group in 
the basal forebrain, resembles the nucleus basalis of Meynert, and we focus on brain volume in 
this structure as a potential biomarker for AD (Mesulam, Mufson, Levey, & Wainer, 1983). To 
obtain volume measurements from the Ch4 region, we used DARTEL to perform voxel based 
morphometry (VBM). In this process, all downloaded T1 MRI images were normalized into 
standard Montreal Neurological Institute (MNI) space. Each voxel in these structural images was 
assigned a metric (VBM parameter) based on the extent to which the voxel was warped to fit the 
standard MNI space template, and these metrics serve as a relative measure of brain volume. 
After normalizing the MRI images to MNI space, a mask was created for the Ch4 region using 
the SPM Anatomy Toolbox. This mask specified which voxel measurements corresponded to the 
Ch4 region, and the VBM parameters within the mask were extracted as measurements of raw 
relative basal forebrain volume. To standardize basal forebrain volume based on each subject’s 
brain size, the VBM parameters were divided by total brain volume measurements provided by 
the ADNIMERGE dataset. At the conclusion of this process, basal forebrain volume measures 
were subtracted at various MRI visits (depending on available data) to derive a measure of 
change in basal forebrain volume. 
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Data Analysis: MVPA 
After obtaining biomarker data on plasma cortisol level and change in basal forebrain volume, 
we used multivariate pattern analysis (MVPA) to determine the predictive validity of each 
biomarker in AD or CN classification. Figure 1 refers to a convenient image that explains the 
intuition behind the MVPA machine learning model (Pereira, Mitchell, & Botvinick, 2009). 
Measures of cortisol and basal forebrain change were independently fed into the MVPA 
algorithm in order to derive measures of classification accuracy. Cortisol measures were 
provided to the MVPA algorithm to obtain a classification accuracy to evaluate how well the 
model could distinguish between AD and CN individuals on the basis of variation in these 
measures. Thereafter, basal forebrain changes were provided to the MVPA algorithm to obtain a 
classification accuracy by which the model could identify AD and CN individuals from the 
variation in these measures. To obtain classification accuracy, the algorithm first partitioned the 
data set (cortisol, basal forebrain change) into a testing set and training set. The algorithm then 
associates variation in the data with a particular label (AD or CN). Finally, the algorithm 
calculates a classification accuracy based on how well it correctly identified the individuals in 
the testing set with the appropriate AD or CN label. Thus, classification accuracy serves as a 







Figure 1. MVPA Classification. This image depicts the general mechanism by which MVPA operates. A set of data 
(biomarker data in the case of this study) is fed into the classifier, along with each of the respective labels (AD or 
CN). The classifier partitions the data set into training data and testing data. The classifier “learns” to associate 
variation in the data to a particular label then “tests” itself on the testing data set. The classification accuracy is then 




Data Analysis: Establishing Significance 
In order to determine whether the MVPA algorithm’s classification accuracy was significantly 
above chance, an empirical p-value was determined. To establish the p-value, an MVPA 
scrambling analysis was run. In the scrambling analysis, the data labels of the training set (AD or 
CN) were scrambled in such a way that a label was randomly assigned to each individual’s data 
profile. Thus, an individual who was truly labeled “AD” might be randomly assigned a “CN” 
label as a consequence of the scrambling. In doing so, the MVPA algorithm is unable to 
consistently associate variation in the data to a particular data label, and it effectively “guesses” 
whether an individual is AD or CN when testing itself on the testing data set. As part of the 
scrambled analysis, 100 independent iterations were run. To establish a p-value, the number of 
instances a particular scrambling iteration yielded a classification higher than the unscrambled 
analysis was divided by the total number of iterations for the scrambling analysis (100). 
















Experimental Validation of MVPA 
Before evaluating the predictive potential of cortisol and basal forebrain degeneration in 
Alzheimer’s Disease identification, an experimental validation of MVPA was required. 
Experimental validation occurred by running an MVPA model using traditional markers of 
Alzheimer’s Disease to determine whether the model was capable of successfully distinguishing 
between AD and CN individuals, thereby replicating the sample’s diagnostic results. In order to 
do this, two traditional markers of Alzheimer’s Disease were utilized: neuropsychological scores 
and brain volumes. Two separate MVPA analyses were run, one analysis containing 
neuropsychological scores and another analysis containing brain volumes (Figure 2).  
In the MVPA analysis containing neuropsychological scores, data collected from three cognitive 
assessments were input for the classifier to use to distinguish AD and CN patients: CDR-SB, 
ADAS 11, and ADAS 13 (Samtani, Raghavan, Novak, Nandy, & Narayan, 2014; Kueper, 
Speechley, & Montero-Odasso, 2018). The MVPA classifier trained on data from these three 
cognitive assessments was able to distinguish between AD and CN with 99.01% accuracy 
(Figure 2).  
In the MVPA analysis containing brain volumes, volume measurements from the entorhinal 
cortex and hippocampus were used as inputs for the algorithm. These areas have been 
characteristically associated with Alzheimer’s Disease based on previous research (Du et al., 
2001). The MVPA classifier trained on brain volume data was able to distinguish between AD 
and CN subjects with 85.20% accuracy (Figure 2). 
The high classification accuracy (99.01%, 85.20%) by the MVPA algorithm when trained on 
neuropsychological scores and brain volumes indicates the validity of using this approach for our 
experimental study. These tests were deliberately circular and were designed to demonstrate that 
the algorithm could use variation in neuropsychological scores and brain volumes to replicate the 
diagnoses assigned to the subjects in the first place. As a result, the high classification accuracy 
demonstrates the ability of the MVPA approach to correctly distinguish AD and CN individuals 
based on traditional Alzheimer’s Disease markers. Thus, the use of MVPA to explore the more 
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Figure 2. Classification Accuracy of Traditional AD Biomarkers. This graph indicates the MVPA classification 
accuracy of Alzheimer’s (AD) and healthy (CN) patients on the basis of two traditional markers of Alzheimer’s 
Disease: neuropsychological scores and brain volumes. Neuropsychological scores were obtained from the subjects’ 
performance on cognitive assessments as measured by CDR-SB, ADAS 11, and ADAS 13. The brain volumes used 
in the MVPA analysis include volume measurements gathered from the entorhinal cortex and hippocampus. MVPA 
classification accuracy when trained on neuropsychological scores was 99.01%, while MVPA classification 
accuracy when trained on brain volumes was 85.20%.  
 
MVPA Cortisol Analysis  
To test the predictive validity of cortisol in distinguishing between AD and CN patients, a 
MVPA classification algorithm using cortisol as the only feature was run. Through this 
approach, the extent to which the classifier is capable of accurately identifying AD and CN 
subjects on the basis of variation in cortisol values could be investigated.  
The MVPA analysis revealed that the algorithm could distinguish between AD and CN subjects 
with 55.24% accuracy. Scrambling analysis revealed that the classification accuracy considered 




























Classification Accuracy for Traditional AD Biomarkers
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classification of 49.89%, the data were not above chance at a statistically significant level (p = 
0.14) (Figure 3).  
 
 
Figure 3. Classification Accuracy of Cortisol and Scrambled Analyses. This graph indicates the MVPA 
classification accuracy of Alzheimer’s (AD) and healthy (CN) patients on the basis of cortisol, a physiological 
biomarker of stress. The MVPA analysis indicated 55.24% classification accuracy for cortisol. The scrambling 
analysis of cortisol established chance at 49.89%. While the classification accuracy is above chance, the results were 
not significantly above chance (p = 0.14). 
 
 MVPA Basal Forebrain Degeneration Analysis  
To evaluate the strength of the predictive nature of basal forebrain degeneration in identifying 
AD and CN individuals, an MVPA classification algorithm using change in basal forebrain 
volume over time (from repeated MRI visits) was run. Using this approach, the success with 
which the classifier can correctly distinguish AD and CN subjects based on change in basal 




























Classification Accuracy for Cortisol vs. Scrambling
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The MVPA analysis for basal forebrain change showed that the algorithm was able to identify 
AD and CN subjects with 68.09% accuracy. Scrambling analysis for basal forebrain change 
demonstrated that “chance” was 49.88%. The data show that the 68.09% MVPA classification 
accuracy based on basal forebrain change is greater than chance at a statistically significant level 
(p < 0.005) (Figure 4). The directionality of the relationship between basal forebrain change and 
AD vs. CN classification was also confirmed: negative values (indicating basal forebrain 










Figure 4. Classification Accuracy of Basal Forebrain (BF) Change and Scrambled Analyses. This graph indicates 
the MVPA classification accuracy of Alzheimer’s (AD) and healthy (CN) patients on the basis of basal forebrain 
change. MVPA classification accuracy for basal forebrain change was 68.09%, while scrambling (chance) 
performance was 49.88%. The difference in basal forebrain change and scrambling analysis was statistically 
significant (p < 0.005).  
 
 
Confusion Matrix Analyses  
Following an analysis of the MVPA classification accuracy, confusion matrices for cortisol and 
basal forebrain change were also analyzed. Confusion matrices offer unique insight, helping 




























Classification Accuracy for BF Change vs. Scrambling
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deeper into what the classification accuracy entails for each category (AD or CN), and the 
information that comes from these analyses reveals more about the ability of these biomarkers to 
distinguish between healthy and pathological forms of aging. Based on the data provided to the 
MVPA classifier (cortisol or basal forebrain change), the confusion matrix analyses provide 
information about how often the classifier correctly classified AD individuals, correctly 
classified CN individuals, misclassified AD individuals as CN individuals, and misclassified CN 
individuals as AD individuals.  
The confusion matrix for cortisol reveals that, based on the variation in cortisol levels, the 
classifier correctly recognized AD patients only 50.99% of the time. In contrast, the classifier 
correctly classified CN patients at a much higher rate, at 67.88% of the time. Furthermore, the 
classifier was more likely to call an AD patient CN (49.01%) than a CN patient AD (32.12%) 
(Table 1).  
 
Table 1. Confusion matrix, expressed as percentages (%), for cortisol MVPA classification. 
 
 AD Guess  CN Guess  
AD True 50.99 49.01 
CN True 32.12 67.88 
 
 
The confusion matrix for basal forebrain change reveals a similar pattern to that of cortisol. 
Based on variation in basal forebrain change, the classifier correctly classified CN patients 
(77.36%) more often than it correctly classified AD patients (56.10%). In addition, AD patients 
were more likely to be misidentified as CN patients (43.90%) than CN patients were to be 





Table 2. Confusion matrix, expressed as percentages (%), for basal forebrain change MVPA 
classification 
 
 AD Guess  CN Guess  
AD True 56.10 43.90 




















This study’s approach involved independently testing whether cortisol and basal forebrain 
degeneration were capable of serving as indicators of Alzheimer’s Disease by analyzing the 
classification accuracy of each biomarker. Importantly, the results have revealed that basal 
forebrain degeneration classification accuracy for Alzheimer’s Disease identification is 
significantly above chance (p < 0.005). While classification accuracy for basal forebrain 
degeneration (68.09%) is not as high as traditional markers of AD (neuropsychological scores, 
99.01%; entorhinal cortex and hippocampal volume, 85.20%), the above chance classification 
accuracy for this biomarker points to its potential benefit as a biomarker that can help play a role 
in the identification of AD. In addition, the directionality of this relationship was found to be 
consistent with relevant literature that suggests that reduction in basal forebrain volume is 
indicative of Alzheimer’s Disease development (Schmitz et al., 2016; Paul, Jeon, Bizon & Han, 
2015). The findings from our study advocate not only for more research to be conducted on how 
basal forebrain degeneration is specifically implicated in AD pathogenesis, but also for how 
diagnostic practice within medicine may be able to utilize basal forebrain degeneration to 
provide additionally relevant evidence to help inform diagnoses of Alzheimer’s Disease and 
healthy aging. In particular, because our study has demonstrated that basal forebrain 
degeneration is informative for AD pathological characterization, the results also help validate 
AD therapeutic initiatives focused on addressing basal forebrain degeneration. 
While basal forebrain degeneration MVPA classification revealed above chance accuracy, 
cortisol MVPA classification failed to reveal above chance classification accuracy (55.24%, p = 
0.14). This result was surprising on account of the variety of research published establishing the 
relevance of cortisol in AD pathogenesis (Ennis et al., 2017; Popp et al., 2009; Green, Billings, 
Roozendaal, McGaugh, & LaFerla, 2006). However, it is important to note that the 55.24% 
classification accuracy was still trending above chance, and the lack of statistical significance 
could be attributed to limitations within the study. In particular, the cortisol data utilized in this 
analysis came from plasma measurements, rather than from cerebrospinal fluid (CSF). Because 
CSF is more closely associated with the central nervous system than plasma, CSF cortisol 
measures could be a more accurate representation of the cortisol profile of each subject (Popp et 
al., 2009). Consequently, an MVPA analysis that utilizes CSF cortisol as opposed to plasma 
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cortisol may provide a higher (potentially significant) classification accuracy, thereby adding 
more value to the diagnostic role cortisol can play in AD identification. Fundamentally, the 
results from the cortisol MVPA analysis call for more research to be done in order to evaluate 
the extent to which cortisol may serve as a predictor of Alzheimer’s Disease. In doing so, the 
manner in which cortisol and life-long stress may contribute to AD pathogenesis and 
pathological identification can become better clarified. 
While the MVPA analysis of cortisol was not significantly above chance (p = 0.14), the 
55.24% classification accuracy still warranted further exploration. As such, the confusion matrix 
for cortisol MVPA classification provided important insight into how the classifier performed 
when using cortisol to discriminate between AD and CN subjects. The most glaring observation 
of this analysis was the lack of symmetry within the confusion matrix: AD patients were 
correctly classified 50.99% of the time, while CN patients were correctly classified 67.88% of 
the time.  When observing this dissymmetry, it became apparent that there was more to the 
cortisol biomarker of Alzheimer’s Disease. Based on the confusion matrix analysis, cortisol 
variability in healthy (CN) patients was much better characterized for the classifier than cortisol 
variability in AD patients; this is evidenced by the fact that CN patients had a higher chance of 
being correctly classified (67.88%) than AD patients (50.99%). Similarly, MVPA analysis of 
basal forebrain degeneration revealed that CN patients also had a higher chance of being 
correctly classified (77.36%) than AD patients (56.10%). These data highlight an important 
finding: cortisol and basal forebrain degeneration variability in individuals who age healthily is 
much less variable than that of individuals who age pathologically (those who have AD). This 
finding could hold clinical relevance, as measures of cortisol and basal forebrain degeneration 
might be able to help physicians discern whether a given patient is likely aging in a healthy 
manner.  
Furthermore, the classifier’s success in associating cortisol and basal forebrain degeneration 
variability in CN patients, while failing to successfully associate cortisol and basal forebrain 
degeneration variability in AD patients, is particularly interesting. This lack of symmetry helps 
advise future directions for the project. In particular, exploring the underlying influences that 
could explain why the MVPA cortisol classifier and MVPA basal forebrain degeneration 
classifier correctly characterizes some AD subjects, while incorrectly classifying other subjects, 
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is a logical next step given these data. For example, a multitude of factors including age, brain 
volume, and pathophysiological characteristics of AD could help explain why the MVPA 
cortisol classifier and MVPA basal forebrain degeneration classifier correctly classify some 
individuals, while incorrectly classifying other individuals (that is, why they exhibit AD despite 
having normal levels on these specific measures). The conclusions that come of these retroactive 
analyses have the potential to more specifically investigate the role cortisol and basal forebrain 
degeneration might play in the characterization of Alzheimer’s Disease, helping further inform 
the set of events by which aging populations develop Alzheimer’s Disease.  
Finally, the present study focused on the predictive validity of cortisol and basal forebrain 
degeneration for CN and AD individuals. It is important not to neglect mild cognitive 
impairment (MCI), a diagnostic state that might serve as an intermediate step in the AD 
pathological process (Petersen et al., 1999). Because ADNI data are available for patients with 
MCI, an experimental approach that utilizes a similar framework to the present study but rather 
substitutes CN vs. AD analyses for MCI analyses (CN vs. MCI and MCI vs. CN) constitutes an 
important future direction. The use of an MCI MVPA analysis in the context of cortisol and 
basal forebrain degeneration can help analyze the time course of when these biomarkers play a 
role in AD pathology. Consequently, a mechanistic sequence of events detailing the role that 
cortisol and basal forebrain degeneration in AD progression can arise from an analysis that uses 
MCI patients. Additionally, the results arising from such an analysis can help advise when 
diagnostic approaches using cortisol and basal forebrain degeneration may yield the most 
benefit. Results of MCI analyses may also help inform when therapeutic interventions targeting 
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